What is CJC-1295's CAS number?

CAS 863288-34-0 resolves to the 3367.9 Da DAC-free peptide. A second number widely quoted for the DAC form does not resolve to any PubChem record.

So how do I identify which form I have?

By molecular weight: 3647.2 with DAC, 3367.9 without. That is measured rather than transcribed and cannot be confused.

Is ipamorelin's identity similarly confused?

No. CAS 170851-70-4 resolves cleanly to CID 9831659 at 711.9 Da with no contradictions.

CJC-1295 CAS Number and Chemical Identity

The short answer

CAS 863288-34-0 resolves to PubChem CID 56841945 at 3367.9 Da, the DAC-free peptide. A second CAS number widely quoted for the DAC form does not resolve to any PubChem record. Given that, molecular weight is a more reliable identifier than either CAS or name.

Key facts

CAS 863288-34-0: CID 56841945, 3367.9 Da
CJC-1295 with DAC: CID 91971820, 3647.2 Da
Ipamorelin CAS: 170851-70-4 → CID 9831659
Ipamorelin MW: 711.9 Da, C38H49N9O5
Reliable discriminator: Molecular weight
Unreliable: Names and, here, CAS numbers

The identifier problem

This category has the messiest identity situation in the library. CAS 863288-34-0 resolves to a 3367.9 Da compound (the DAC-free peptide) while carrying synonyms on PubChem that describe it both as with DAC and as no DAC. A second CAS number frequently quoted for the DAC form returns no PubChem record at all. Neither the names nor the registry numbers can be relied on in isolation.

What can be relied on

Molecular weight, because it is measured rather than transcribed. 3647.2 is the DAC form; 3367.9 is not. A 279.3 Da gap is far outside any instrument's ambiguity. Where a certificate reports mass and a label reports a name, the mass is the field that describes the material in front of you.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £36.99

Ipamorelin is clean by comparison

CAS 170851-70-4 resolves cleanly to PubChem CID 9831659 at 711.9 Da, C38H49N9O5. One name, one number, one compound, no contradictions. It matters because it shows the CJC-1295 mess is specific to that compound rather than general to the category.

Confirming identity analytically

Mass spectrometry against the expected value for whichever form is claimed. For ipamorelin, 711.9. For the GHRH analogue, 3647.2 or 3367.9 depending on the form. The peptides contain no cysteine, so no disulfide species should appear; CJC-1295's substitutions remove the methionine native GRF(1-29) carries, so the +16 Da oxidation satellite should also be absent.

Confirming purity

Reverse-phase HPLC. A 29-residue peptide is a substantial synthesis with real scope for deletion sequences, so the purity figure carries more information here than for the short peptides elsewhere in this library. Ipamorelin at five residues is a much easier synthesis and correspondingly high purity is expected.

Frequently asked questions

What is CJC-1295's CAS number?: CAS 863288-34-0 resolves to the 3367.9 Da DAC-free peptide. A second number widely quoted for the DAC form does not resolve to any PubChem record.
So how do I identify which form I have?: By molecular weight: 3647.2 with DAC, 3367.9 without. That is measured rather than transcribed and cannot be confused.
Is ipamorelin's identity similarly confused?: No. CAS 170851-70-4 resolves cleanly to CID 9831659 at 711.9 Da with no contradictions.

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release. CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
▸Ghrelin-receptor binding assays for Ipamorelin analogue development
▸Analytical HPLC method development for lipidated GHRH analogues
▸Stability testing under refrigerated storage

Handling checklist

✓Store lyophilised at −20 °C long-term
✓Reconstitute in bacteriostatic water; both peptides dissolve readily
✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
✓Do not use for human administration (research reference only)

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA. The two have very different pharmacokinetics.

✗ Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a), a separate pathway from CJC-1295.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum